


LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,206	95,874	360	3.75
Merative CCAE	9,690	7,791	23	2.95
Merative MDCD	1,662	1,033	9	8.71
Merative MDCR	1,083	846	6	7.09
Optum Clinformatics	7,389	5,531	37	6.69
Optum EHR	9,946	2,757	29	10.52
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

